



31 October 2025

Quarterly Activity Report - Period ending 30 September 2025

Skin Elements Limited (ASX: SKN) (Skin Elements, the Company), a leader in the development of Australian all natural biotechnology, is pleased to present its Quarterly Activity Report for the period ending 30 September 2025.

Quarterly Highlights

- **ECO Nurture Kiwifruit Evaluation Complete**
ECO-Nurture sustainable, horticultural plant biostimulant now being delivered to kiwifruit orchards in New Zealand for the 2025/26 growing season.
- **SuprCuvr high performance disinfectant cleaner safeguards Melbourne Trains**
SuprCuvr 3 in 1 disinfectant cleaner adopted for daily cleaning and disinfecting of Metro Trains Melbourne urban rail network after a two year assessment.
- **Soleo Organics Sunscreen Delivers Performance**
Soleo Organics high performance sunscreen range continues to deliver independently certified formulations for domestic market and opportunity for white label sunscreen range in large-scale retail pharmacy sector
- **R&D Funding Underpins Development Costs**
Approval received for R&D Rebate of \$610k in relation to qualifying R&D expenditure for the FY 2025 year with funds expected to be received in the current quarter.
- **Commitments for Strategic Placement to raise \$2.5 million**
Skin Elements secured commitments for a \$2.5m placement subject to shareholder approval to accelerate growth and launch into commercialisation and also agreed to \$1m debt for equity to key director and management subject to shareholder approval.

Commenting on the quarter, Skin Elements Executive Chairman Mr Peter Malone said;

“The quarter marked a watershed period for Skin Elements with strong field evaluation results from our SuprCuvr and ECO Nurture programmes, and independent laboratory verification of the performance of our Soleo Organics sunscreen formulations, which validates our three phase development process into commercial scale sales. Backed by a solid financial position, which has been enhanced by our recent \$2.5 placement, we are now positioned for our sales programmes to drive growth in 2026.”

Natural Science by Skin Elements

SE Formula™ – the Cornerstone of our Business

The SE Formula has been developed by Skin Elements over the last 18 years and is the core of every natural product the Company develops. Products with the SE Formula™ have scientifically proven efficacy while using only natural and plant-based ingredients and have come to be trusted by consumers.

To date, the Company has developed four highly effective core **GREEN - Tech** formulas, with each providing viable, efficacious, environmentally friendly alternatives to widely used chemical based products in mass markets globally. These formulas form the basis of Skin Elements' product range - Soléo Organics, SuprCuvr, ECO-Nurture and PapayaActivs Therapeutics – and underpin its value proposition.

ECO-Nurture Kiwifruit Evaluation Complete

ECO-Nurture is a sustainable, horticultural-specific plant bio stimulant product developed from the plant-based SE Formula™ biotechnology as an effective alternative to chemical-based agricultural sprays currently used in crop disease protection globally.

Over the past three growing seasons, over 6,400 litres of ECO-Nurture concentrate have been delivered to 120 kiwifruit orchards in New Zealand for application and assessment, with positive outcomes on kiwifruit plant protection and productivity without any chemical residue. A number of orchard managers have incorporated ECO Nurture into their kiwifruit spray protection programmes and ECO Nurture has been approved under Zespri Crop Allowed Other Compounds (AOC) Approval List. Headquartered in New Zealand, Zespri is the world's largest marketer of kiwifruit with over \$5 billion in sales annually.

Skin Elements continues to work through the certification for the widespread adoption of ECO-Nurture for the New Zealand kiwifruit industry under approved Zespri Crop Protection Standards.

Skin Elements is seeking to commence the commercial roll-out of ECO-Nurture for the 2025/26 New Zealand kiwifruit growing season.

SuprCuvr high performance disinfectant cleaner safeguards Melbourne Trains

SuprCuvr is a TGA registered hospital-grade disinfectant made from the Company's proprietary 100% plant-based formula. It combines the world's highest level of efficacy against viral and bacterial infection with a 100% plant-based organic input certified formula to present a significant market opportunity as a chemical-free disinfectant in large-scale settings such as food manufacturing, hospitality retailing businesses, public transport and health.

SuprCuvr is listed on the TGA's Australian Register of Therapeutic Goods (ARTG) in Australia and has Ministry of Primary Industry (MPI) registration in New Zealand.

Following a two year assessment, Spotless has adopted SuprCuvr for daily cleaning and disinfecting of suburban train carriages and stations in the Metro Trains Melbourne urban rail network, supplied and distributed by Melbourne Cleaning Supplies (MCS) part of the Bunzl global business cleaning and disinfectant solutions group.

Over the past two years, over 6,000 litres of SuprCuvr concentrate high performance 3 in 1 surface cleaner, glass cleaner and disinfectant cleaner has been delivered to Spotless for evaluation of cleaning and disinfecting train services and high schools in Melbourne.

Spotless, a wholly owned subsidiary of Downer EDI Ltd, is the largest integrated facilities service provider throughout Australia and New Zealand across government, education, healthcare and aged care.

Soléo Organics Sunscreen Delivers Performance

Soléo Organics is an award-winning, natural and organic sunscreen formulation, providing a highly effective, high performance chemical-free sunscreen range. It was the first application borne out of Skin Elements' SE Formula™ research and development program. Soleo Organics has been rated as the number one sunscreen globally out of 1,800 sunscreens by Environmental Working Group (EWG), Washington Post (Sprig) N°1 sunscreen, a finalist in the Clean Beauty Awards, the UK Global Health & Pharma Awards – Best Natural Sunscreen Brand and most recently independently verified by Consumer NZ. Soleo Organics sunscreen formulations are independently tested and certified by the world's leading testing laboratory to ensure reliability and integrity.

Skin Elements is working on the development of a new, premium upgraded Soléo Organics sunscreen for the domestic market, and negotiations continue with a leading health retail group in the United Kingdom for distribution of the Soléo Organics sunscreen formulation under white label.

Skin Elements will update the market on any material progress on these, or any other, sales or distribution opportunities.

PapayaActives Therapeutics

During the quarter, Skin Elements continued to progress improvements in the PapayaActives formulation and expansion of the product range. The Company also undertook small scale test market of skincare ranges through its online store.

PapayaActives combines a high concentration of natural pawpaw extract with other active natural ingredients to help relieve the symptoms of skin conditions, like psoriasis, rashes, eczema, assist in healing of minor burns and wounds, and relieve mild muscle, joint and arthritic pain. PapayaActives is listed on the ARTG.

Research & Development Rebate and Radium Facility Underpins Development Costs

The Company's innovative research and development programmes for its natural SE Formula™ Biotechnology sees it eligible for the Federal Government's R&D Rebate.

During the quarter, Skin Elements received approval for R&D Rebate of \$610k in relation to qualifying R&D expenditure for the FY 2025 year, with the funds to be received in the current quarter.

\$2.5m Strategic Placement Strengthens Financial Position

Skin Elements secured firm commitments for \$2.5 million (before costs) through a two tranche placement to professional and sophisticated investors at \$0.002 per share. Tranche One of \$315,000 have been issued under the Company's ASX LR7.1 and 7.1A capacity, with Tranche Two of \$2,185,000 subject to shareholder approval, to be sought at the upcoming 2025 Annual General Meeting.

The placement proceeds will enable the Company to drive towards commercialisation of its product range which is underpinned by its award winning SE Formula™ all natural antimicrobial biotechnology, and provide additional working capital.

In addition, the Company has agreed to issue shares at \$0.002 to key director and management in satisfaction of \$1 million in unpaid debt, subject to shareholder approval which will be sought at the upcoming 2025 Annual general Meeting.

Summary of Operating Cashflows

The Company's progression through its three phase research program is reflected in the operating cashflows for the quarter, which included customer receipts of \$127k and operational cash outflows included \$118k invested in product manufacturing, staff, research & development, and \$58k for marketing, premises, administration and corporate finance costs. Net cash outflows from operating activities for the quarter were \$49k. The Company continues to manage operational cashflows in line with operational and financing cash inflows.

In addition, during the quarter \$9k was paid to Directors for services and \$29k was paid to entities associated with the Directors for repayment of borrowings related to R&D project costs.

This announcement has been approved by the Board of Directors of Skin Elements Limited.

END

For further information please contact

Peter Malone
Executive Chairman
Skin Elements Limited
T: +61 439 430 770

E: peter@skinelementslimited.com

Media and Investor Inquiries

James Moses
Mandate Corporate
T: +61 420 991 574

E: james@mandatecorporate.com.au

About Skin Elements

Skin Elements (ASX: SKN) is an award winning Australian owned and operated ASX-listed natural biotechnology company focused on the development of its SE Formula™ Biotechnology. Skin Elements world leading innovative approach to research and development of plant-based and organic sourced ingredients has enabled the creation of a portfolio of all natural plant based formulations that have global applications. Its flagship formulations have delivered products that include the SuprCuvr listed on ARTG, hospital-grade plant-based disinfectant, ECO-Nurture plant bio-stimulant, Soléo Organics natural and organic sunscreen, PapayaActivs natural therapeutics skincare products and the Elizabeth Jane Natural Cosmetics brand.

Further information is available via the Company website: <http://skinelementslimited.com> and on the Company online store: www.sknlife.com.au.



Appendix 4C

Name of entity
SKIN ELEMENTS LIMITED (ASX:SKN)

ABN
90 608 047 794

Quarter ended (**Current quarter**)

30 September 2025

Consolidated statement of cash flows		Current Quarter \$A'000	Year to date (3 Months) \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers	127	127	
1.2 Payments for:	-	-	
(a) research and development	(20)	(20)	
(b) product manufacturing and operating costs	(7)	(7)	
(c) advertising and marketing	(1)	(1)	
(d) leased assets	(17)	(17)	
(e) staff costs	(91)	(91)	
(f) administration costs	-	-	
(g) corporate costs	(39)	(39)	
1.3 Dividends received (see note 3)	-	-	
1.4 Interest received	-	-	
1.5 Interest and other costs of finance paid	(1)	(1)	
1.6 Income taxes (paid) / refunded	-	-	
1.7 Government grants and tax incentives	-	-	
1.8 Other: (provide details if material)	-	-	
1.9 Net cash from / (used in) operating activities	(49)	(49)	
2. Cash flows from investing activities			
2.1 Payments to acquire:			
(a) entities	-	-	
(b) businesses	-	-	
(c) property, plant and equipment	-	-	
(d) investments	-	-	
(e) intellectual property	-	-	
(f) other non-current assets	-	-	
2.2 Proceeds from disposal of:			
(a) entities	-	-	
(b) businesses	-	-	
(c) property, plant and equipment	-	-	
(d) investments	-	-	
(e) intellectual property	-	-	
(f) other non-current assets	-	-	
2.3 Cash flows from loans to other entities	-	-	
2.4 Dividends received (see note 3)	-	-	
2.5 Other (provide details if material)	-	-	
2.6 Net cash from / (used in) investing activities	-	-	

Consolidated statement of cash flows

	Current Quarter \$A'000	Year to date (12 Months) \$A'000
3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	(4)	(4)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	(4)	(4)
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	60	60
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(49)	(49)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(4)	(4)
4.5 Effect of movement in exchange rates on cash held	-	-
4.6 Cash and cash equivalents at end of period	7	7

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	7	60
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details):	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	7	60

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

Current quarter \$A'000
9
Nil

Note: if any amounts are shown in items 6.1 and 6.2 your quarterly activity report must include a description of, and an explanation for, such payments

During the quarter \$9k was paid to Directors for services and \$29k was paid to entities associated with the Directors for repayment of borrowings related to project costs.

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify): R&D Rebate Advance Facility	610	433
7.4 Total financing facilities	610	433

- 7.5 Unused financing facilities available at quarter end 177
- 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

■ **R&D Rebate Advance Facility Terms and conditions:**

<i>Terms</i>	Up to 18 months.
<i>Total facility</i>	\$610K based on eligible R&D spend.
<i>Drawdown</i>	As at 30 June 2025, \$433K has been drawn down.
<i>Security</i>	The facility is secured against the R&D Tax Rebate based on eligible R&D spend. The facility and interest is repaid on receipt of the R&D Rebate.
<i>Interest Rate</i>	15% p.a. pro rata.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(49)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	7
8.3 Unused finance facilities available at quarter end (Item 7.5)	177
8.4 Total available funding (Item 8.2 + Item 8.3)	184
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	3.75

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

- 8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:
- Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

N/A

- Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

N/A

- Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: Friday, 31 October 2025

Authorised by: The Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.